We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
an outline of formulations change during development, details of the kind of Formulation changes from Phase 1 clinical study to commercialization of drug, Formulation changes Post-Approval and Commercialization.
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.
Several pharmaceutical and biotechnology companies in China are actively involved in the research and development of Central Nervous System (CNS) drugs.
AdvertisingEmail to: Julia.zhang@imsinoexpo.com
Media CooperationEmail to: Jennifer.Yang@imsinoexpo.com
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!